Software demonstrations: Olympia foyer (Level -1)
Kajsa Harling Perl speaks NONMEM (PsN) and Xpose
Marc Lavielle Analysing population PK/PD data with MONOLIX 4.0
Joakim Nyberg PopED - An optimal experimental design software
Coen van Hasselt Piraña: The flexible modeling environment for NONMEM
Stephane Vellay Pipeline Pilot - Data Integration, Analysis, and Reporting Platform
Posters: Absorption and physiology-based PK
I-10 Christian Bartels Population PK Model for Pooled Data of Different Oral Diclofenac Formulations
I-35 Vicente G. Casabo Bioequivalence trials simulation to select the best analyte for acetylsalicylic acid
I-62 Kristin Dickschen Pharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites
II-20 Ludivine Fronton Monoclonal Antibody Disposition beyond Target Binding: Impact of FcRn on Clearance and Derivation of Mechanistic Compartment Models
II-40 Emilie Hénin Meta-analysis of Magnetic Marker Monitoring data to characterize tablet movement through the gastrointestinal tract
III-9 Donghwan Lee Development of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics
III-26 Eugeniy Metelkin A Systems Pharmacology Model of Anandamide Dynamics After FAAH Inhibitor Administration
III-35 Christoph Niederalt Development of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats
III-40 Kayode Ogungbenro A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: an evaluation using simulation
III-54 Anna Pieper Development of a PBPK model of doxorubicin
IV-8 Alexander Solms Modelling Inter-Individual Variability in PBPK Models and Deriving Mechanistic Covariate Models for PopPK
IV-21 Sonya Tate The Importance of Enterohepatic Recirculation in the Disposition of Pravastatin and Rosuvastatin: A Physiologically-Based Pharmacokinetic Modelling Approach
IV-47 Thomas Wendl Development of a physiologically-based pharmacokinetic (PBPK) model for Moxifloxacin and its metabolites in healthy adults
IV-65 Kirill Zhudenkov Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients
Posters: Cardiovascular, QT-prolongation
I-14 Francesco Bellanti Relevance of QT-RR correlations in the assessment of QTc-interval prolongation in clinical trial simulations
I-28 Christine Brandquist PK/PD Modeling of the Effect of Intravenous Doses of Anzemet® (dolasetron mesylate) and Its Metabolite (hydrodolasetron) on the QT Interval in Healthy Subjects
I-37 Anne Chain Can First-Time-In-Human Trials Replace Thorough QT Studies?
I-63 Jeroen Diepstraten Pharmacodynamics of nadroparin using anti-Xa levels in morbidly obese patients upon subcutaneous administration of 5700 IU
II-1 Vincent Dubois Translation of drug-induced QTc prolongation in early drug development.
II-11 Farkad Ezzet Meta-Analysis of Antiplatelets in Patients with Atrial Fibrillation: A survival Model
II-44 Eleanor Howgate PKPD Modelling Of Cardiovascular Safety Pharmacology Data
II-55 Helene Karcher Probabilistic risk assessment for QT prolongation and heart rate increase
III-41 Oliver Ackaert Population modelling of blood pressure: assessing clinically important factors for cardiovascular diseases
IV-6 Nelleke Snelder Quantitative understanding of drug effects on the interrelationship between mean arterial blood pressure, cardiac output and total peripheral resistance
IV-36 Piet van der Graaf Towards a Thorough Preclinical QT (“TpQT”) study paradigm: Pharmacokinetic-Pharmacodynamic (PKPD) Modelling of QTc Effects of Moxifloxacin in Cynomolgus Monkeys
Posters: CNS
I-22 Irina Bondareva Sequential Interacting Multiple Model (IMM) Bayesian Analysis of Carbamazepine and Valproate Repeated Therapeutic Drug Monitoring (TDM) Data from Epileptic Patients
I-32 Jacob Brogren Separate vs. simultaneous analysis of co-primary endpoints in Alzheimer’s disease clinical trials
I-56 Elizabeth de Lange Mechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback
II-25 Martin Gnanamuthu Johnson Predicting Dopamine D2 Receptor Occupancy in humans using a physiology-based approach
II-26 Martin Gnanamuthu Johnson Pharmacokinetic-Pharmacodynamic Modeling of Dopamine D2 Receptor Occupancy in humans using Bayesian modeling tools
II-34 Zheng Guan Population pharmacokinetic and pharmacodynamic analysis of cortisol in serum and saliva in healthy male volunteers after an acute 5-hydroxytryptophan (5-HTP) challenge test
II-42 Eef Hoeben Population pharmacokinetic analysis of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia
II-48 Masoud Jamei A physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain
II-65 Huub Jan kleijn Development and Application of a Semi-Mechanistic Model for Modulation of Amyloid-beta in Cerebrospinal Fluid after Inhibition of γ-secretase.
III-16 Arianna Madrid Modelling the sleep effects of Zolpidem in rats using non-homogeneous Markov chain models
III-25 François Mercier A Bayesian meta-analysis of longitudinal lesion count data in multiple sclerosis patients
III-56 Venkatesh Pilla Reddy Exposure-Response Relationship of Typical and Atypical Antipsychotics Assessed by the Positive and Negative Syndrome Scale (PANSS) and its Subscales
III-58 Bart Ploeger Confirmation of symptomatic and disease modifying effects of levodopa using the ELLDOPA study
IV-15 Ahmed Suleiman A Mixed-Effects Markov Model for Characterizing the Time Course of the Transitions between Different Extrapyramidal Side Effects Severity Levels
IV-19 Stina Syvänen Quinidine Microdialysis Reveals Altered P-glycoprotein Function in Epileptic Rats in the Brain Parenchyma Rather than at the Blood-Brain Barrier
IV-30 Karin Tunblad A pharmacokinetic/pharmacodynamic analysis of central and peripheral effects of GSK3 inhibitors
Posters: Endocrine
I-45 Steve Choy Application of an integrated glucose-insulin model to investigate the effects of glibenclamide and its active metabolites on postprandial glucose and insulin concentrations in healthy volunteers
II-7 Petra Ekerot Mechanism-based Pharmacokinetic-Pharmacodynamic Feedback Model of Thyroid Hormones after Inhibition of Thyroperoxidase in the Dog. Cross-species Prediction of Thyroid Hormone Profiles in Rats and Humans.
III-6 Anna Largajolli Meal Tolerance Test (MTT): Nonlinear Mixed-Effects Modeling of Insulin Secretion
III-29 Jonas Bech Møller Model-based Analysis of the GLP-1 Response following an Oral Glucose Tolerance Test (OGTT)
III-46 Joanna Peng A Mechanistic Model for the Effects of A Novel Drug on Glucose, Glucagon and Insulin Applied to Adaptive Phase II Design
III-49 Kirill Peskov A Quantitative Systems Pharmacology Model Provides Insights into